EGFR and non-small cell lung carcinoma: NCT03535363 (phase 1) and NCT03769103 (phase 2) clinical trials are currently in the recruitment phase, which aims to research the efficacy and toxicity of SRS combined with Osimertinib in the treatment of BMs in patients with EGFR-mutant NSCLC.